PRESS RELEASE published on 03/09/2023 at 08:00, 3 years 6 months ago Biophytis présente les résultats positifs de Phase 2-3 COVA à la 21ème Conférence « Lung Science » - ERS 2023
PRESS RELEASE published on 03/02/2023 at 00:00, 3 years 6 months ago Biophytis annonce la signature d’un accord-cadre avec Intsel Chimos, laboratoire pharmaceutique qui exploitera Sarconeos (BIO101) en France pour le traitement des formes sévère de COVID-19
PRESS RELEASE published on 03/02/2023 at 00:00, 3 years 6 months ago Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-1
PRESS RELEASE published on 02/27/2023 at 08:00, 3 years 6 months ago Biophytis: Biophytis démarre le processus règlementaire de demande d’autorisation d’accès précoce en France auprès de la Haute Autorité de Santé (HAS) pour le traitement avec Sarconeos (BIO101) des fo
PRESS RELEASE published on 02/27/2023 at 08:00, 3 years 6 months ago Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of
PRESS RELEASE published on 02/23/2023 at 08:00, 3 years 7 months ago : Biophytis To Host A Combined General Shareholder’s Meeting On March 30, 2023
PRESS RELEASE published on 02/23/2023 at 08:00, 3 years 7 months ago Biophytis annonce la convocation d’une assemblée générale mixte le 30 mars 2023
PRESS RELEASE published on 02/02/2023 at 08:00, 3 years 7 months ago Biophytis: Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19
PRESS RELEASE published on 02/02/2023 at 08:00, 3 years 7 months ago Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19
PRESS RELEASE published on 01/31/2023 at 08:00, 3 years 7 months ago Biophytis publishes its financial results for the first half of 2022
Published on 09/23/2026 at 22:00, 9 hours 32 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 13 hours 7 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 15 hours 50 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 17 hours 1 minute ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 17 hours 2 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/24/2026 at 07:15, 17 minutes ago EQS-Adhoc: Shelly Group SE enters into Investment Agreement with Schneider Electric SE
Published on 09/24/2026 at 07:00, 32 minutes ago flatexDEGIRO sets new cost benchmark for Germany’s Retirement Savings Account (Altersvorsorgedepot)
Published on 09/24/2026 at 07:00, 32 minutes ago Europe’s small & mid caps: Opportunities remain intact in a new investment era
Published on 09/24/2026 at 07:00, 32 minutes ago bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
Published on 09/24/2026 at 07:00, 32 minutes ago bioMérieux lance SPINCHIP® hs-cTnl, une innovation majeure pour le dosage hypersensible de la troponine I cardiaque et l’accélération de la prise en charge des urgences cardiaques
Published on 09/23/2026 at 19:46, 11 hours 46 minutes ago SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 12 hours 18 minutes ago Robust performance from Investments and continued execution of the strategy
